+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Congestive Heart Failure Market by Type, Diagnosis, Treatment, End User - Global Forecast 2025-2030- Product Image
Congestive Heart Failure Market by Type, Diagnosis, Treatment, End User - Global Forecast 2025-2030- Product Image
Sale

Congestive Heart Failure Market by Type, Diagnosis, Treatment, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 195 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6014519
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Congestive Heart Failure Market grew from USD 6.43 billion in 2023 to USD 6.79 billion in 2024. It is expected to continue growing at a CAGR of 7.31%, reaching USD 10.54 billion by 2030.

Congestive heart failure (CHF) refers to a chronic and progressive condition wherein the heart muscle is unable to pump blood efficiently, leading to an inadequate supply of oxygen and nutrients to meet the body's needs. The increasing prevalence of CHF, due primarily to aging populations and rising incidences of comorbidities such as diabetes and obesity, necessitates an expansive market scope that covers therapeutics, diagnostics, and management solutions. Innovations in diagnostic tools, such as predictive analytics and wearable technology, enhance early detection and continuous monitoring, reflecting the necessity for comprehensive management systems. The application of advanced pharmaceuticals, including ACE inhibitors, beta-blockers, and new-generation medical devices like implantable defibrillators and ventricular assist devices, demonstrates the diversified end-use scope aimed at reducing mortality and morbidity. Market growth is significantly influenced by technological advancements and increased health awareness, coupled with increased healthcare expenditure and supportive government policies. However, the market faces challenges like high treatment costs, reimbursement issues, and stringent regulatory requirements that could impede growth. Opportunities lie in personalized medicine, digital health solutions, and telecardiology, which promise to optimize patient outcomes with tailored and accessible care plans. Businesses can tap into these opportunities by investing in research focused on non-invasive diagnostic methods and developing cost-effective treatment alternatives that align with evolving healthcare policies. Continuous innovation in drug formulation and delivery systems, alongside strategic collaborations and partnerships, further provide avenues for market expansion. Despite challenges, such as the slow adoption of health tech in developing regions and increasing competition among manufacturers, the CHF market is robust with potential areas for innovation, particularly in patient-centric solutions and integrated care platforms, fostering an ecosystem where both patient experience and clinical outcomes are prioritized.

Understanding Market Dynamics in the Congestive Heart Failure Market

The Congestive Heart Failure Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising demand for minimally invasive surgeries and heart failure management procedures
    • Expanding healthcare access and improving diagnostic facilities in emerging markets
    • Increasing partnerships and collaborations among pharmaceutical companies for drug development
    • Growing patient awareness and education initiatives regarding early diagnosis and management options
  • Market Restraints
    • Limited availability of specialized healthcare providers with expertise in congestive heart failure management
    • High prevalence of comorbidities complicates congestive heart failure treatment and outcomes, reducing market effectiveness
  • Market Opportunities
    • Integration of artificial intelligence and machine learning in congestive heart failure diagnosis and treatment
    • Advancement of minimally invasive surgical techniques for congestive heart failure treatment
    • Utilization of patient-specific data in personalized congestive heart failure treatment plans
  • Market Challenges
    • Heightened regulatory scrutiny impacting approval and distribution of congestive heart failure therapies
    • Increased competition from emerging biotechnologies and alternative treatments for congestive heart failure

Exploring Porter’s Five Forces for the Congestive Heart Failure Market

Porter’s Five Forces framework further strengthens the insights of the Congestive Heart Failure Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Congestive Heart Failure Market

External macro-environmental factors deeply influence the performance of the Congestive Heart Failure Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Congestive Heart Failure Market

The Congestive Heart Failure Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Congestive Heart Failure Market

The Congestive Heart Failure Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Congestive Heart Failure Market

The Congestive Heart Failure Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Congestive Heart Failure Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen Inc., AstraZeneca, Bayer AG, Biotronik, Boston Scientific Corporation, Bristol-Myers Squibb Company, CVRx, Inc., Eli Lilly and Company, GlaxoSmithKline plc, HeartWare International Inc., Johnson & Johnson, Medtronic plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., ResMed, Sanofi S.A., Teleflex Incorporated, and Thoratec Corporation.

Market Segmentation & Coverage

This research report categorizes the Congestive Heart Failure Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Type
    • Left-Sided Heart Failure
      • Diastolic Heart Failure
      • Systolic Heart Failure
    • Right-Sided Heart Failure
  • Diagnosis
    • Blood Tests
      • BNP Test
      • Electrolyte Level Test
      • NT-proBNP Test
    • Electrocardiogram
    • Imaging Tests
      • CT Scan
      • Echocardiogram
      • MRI
    • Stress Tests
      • Exercise Stress Test
      • Nuclear Stress Test
  • Treatment
    • Medical Devices
      • Cardiac Resynchronization Therapy Devices
      • Implantable Cardioverter Defibrillators
      • Pacemakers
    • Medications
      • ACE Inhibitors
      • Aldosterone Antagonists
      • Beta Blockers
      • Diuretics
      • Vasodilators
    • Surgical Procedures
      • Coronary Bypass Surgery
      • Heart Valve Repair or Replacement
  • End User
    • Ambulatory Surgical Centers
    • Hospitals
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising demand for minimally invasive surgeries and heart failure management procedures
5.1.1.2. Expanding healthcare access and improving diagnostic facilities in emerging markets
5.1.1.3. Increasing partnerships and collaborations among pharmaceutical companies for drug development
5.1.1.4. Growing patient awareness and education initiatives regarding early diagnosis and management options
5.1.2. Restraints
5.1.2.1. Limited availability of specialized healthcare providers with expertise in congestive heart failure management
5.1.2.2. High prevalence of comorbidities complicates congestive heart failure treatment and outcomes, reducing market effectiveness
5.1.3. Opportunities
5.1.3.1. Integration of artificial intelligence and machine learning in congestive heart failure diagnosis and treatment
5.1.3.2. Advancement of minimally invasive surgical techniques for congestive heart failure treatment
5.1.3.3. Utilization of patient-specific data in personalized congestive heart failure treatment plans
5.1.4. Challenges
5.1.4.1. Heightened regulatory scrutiny impacting approval and distribution of congestive heart failure therapies
5.1.4.2. Increased competition from emerging biotechnologies and alternative treatments for congestive heart failure
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Congestive Heart Failure Market, by Type
6.1. Introduction
6.2. Left-Sided Heart Failure
6.2.1. Diastolic Heart Failure
6.2.2. Systolic Heart Failure
6.3. Right-Sided Heart Failure
7. Congestive Heart Failure Market, by Diagnosis
7.1. Introduction
7.2. Blood Tests
7.2.1. BNP Test
7.2.2. Electrolyte Level Test
7.2.3. NT-proBNP Test
7.3. Electrocardiogram
7.4. Imaging Tests
7.4.1. CT Scan
7.4.2. Echocardiogram
7.4.3. MRI
7.5. Stress Tests
7.5.1. Exercise Stress Test
7.5.2. Nuclear Stress Test
8. Congestive Heart Failure Market, by Treatment
8.1. Introduction
8.2. Medical Devices
8.2.1. Cardiac Resynchronization Therapy Devices
8.2.2. Implantable Cardioverter Defibrillators
8.2.3. Pacemakers
8.3. Medications
8.3.1. ACE Inhibitors
8.3.2. Aldosterone Antagonists
8.3.3. Beta Blockers
8.3.4. Diuretics
8.3.5. Vasodilators
8.4. Surgical Procedures
8.4.1. Coronary Bypass Surgery
8.4.2. Heart Valve Repair or Replacement
9. Congestive Heart Failure Market, by End User
9.1. Introduction
9.2. Ambulatory Surgical Centers
9.3. Hospitals
9.4. Specialty Clinics
10. Americas Congestive Heart Failure Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Congestive Heart Failure Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Congestive Heart Failure Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. CONGESTIVE HEART FAILURE MARKET RESEARCH PROCESS
FIGURE 2. CONGESTIVE HEART FAILURE MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
FIGURE 9. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
FIGURE 11. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 13. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. CONGESTIVE HEART FAILURE MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. CONGESTIVE HEART FAILURE MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. CONGESTIVE HEART FAILURE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. CONGESTIVE HEART FAILURE MARKET DYNAMICS
TABLE 7. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIASTOLIC HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SYSTOLIC HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY RIGHT-SIDED HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY BNP TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ELECTROLYTE LEVEL TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY NT-PROBNP TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ELECTROCARDIOGRAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CT SCAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ECHOCARDIOGRAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY MRI, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY EXERCISE STRESS TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY NUCLEAR STRESS TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CARDIAC RESYNCHRONIZATION THERAPY DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY IMPLANTABLE CARDIOVERTER DEFIBRILLATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY PACEMAKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY ALDOSTERONE ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY VASODILATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY CORONARY BYPASS SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HEART VALVE REPAIR OR REPLACEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL CONGESTIVE HEART FAILURE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 85. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 86. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 87. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 88. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 89. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
TABLE 90. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 91. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 92. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 93. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 94. CANADA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 96. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 97. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 98. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 99. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 100. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
TABLE 101. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 102. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 103. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 104. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 105. MEXICO CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 107. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 114. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 116. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. UNITED STATES CONGESTIVE HEART FAILURE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 118. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 119. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 120. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 121. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 122. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 123. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
TABLE 124. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 125. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 126. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 127. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 128. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. ASIA-PACIFIC CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 130. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 131. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 132. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 133. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 134. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 135. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
TABLE 136. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 137. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 138. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 139. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 140. AUSTRALIA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 142. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 143. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 144. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 145. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 146. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
TABLE 147. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 148. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 149. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 150. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 151. CHINA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 153. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 154. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 155. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 156. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 157. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
TABLE 158. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 159. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 160. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 161. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 162. INDIA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 164. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 165. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 166. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 167. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 168. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
TABLE 169. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 170. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 171. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 172. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 173. INDONESIA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 175. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 176. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 177. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 178. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 179. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
TABLE 180. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 181. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 182. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 183. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 184. JAPAN CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 185. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 186. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 187. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 188. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 189. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 190. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
TABLE 191. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 192. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 193. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 194. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 195. MALAYSIA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 196. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 197. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 198. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 199. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 200. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 201. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
TABLE 202. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 203. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 204. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 205. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 206. PHILIPPINES CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 208. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 209. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 210. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 211. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 212. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
TABLE 213. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 214. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 215. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 216. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 217. SINGAPORE CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 219. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 220. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 221. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 222. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 223. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
TABLE 224. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 225. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 226. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 227. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 228. SOUTH KOREA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 230. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 231. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 232. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 233. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 234. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
TABLE 235. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 236. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 237. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 238. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 239. TAIWAN CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 241. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 242. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 243. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 244. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 245. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
TABLE 246. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 247. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 248. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 249. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 250. THAILAND CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 252. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 253. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 254. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 255. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 256. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
TABLE 257. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 258. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 259. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 260. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 261. VIETNAM CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA CONGESTIVE HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 274. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 275. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 276. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 277. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 278. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 279. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
TABLE 280. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 281. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 282. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 283. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 284. DENMARK CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 285. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 286. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 287. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 288. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 289. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 290. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
TABLE 291. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 292. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 293. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 294. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 295. EGYPT CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 296. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 297. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 298. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 299. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 300. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 301. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
TABLE 302. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 303. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 304. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 305. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 306. FINLAND CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 307. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 308. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 309. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 310. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 311. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 312. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
TABLE 313. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 314. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 315. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 316. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 317. FRANCE CONGESTIVE HEART FAILURE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 318. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 319. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY LEFT-SIDED HEART FAILURE, 2018-2030 (USD MILLION)
TABLE 320. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 321. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY BLOOD TESTS, 2018-2030 (USD MILLION)
TABLE 322. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 323. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY STRESS TESTS, 2018-2030 (USD MILLION)
TABLE 324. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 325. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 326. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 327. GERMANY CONGESTIVE HEART FAILURE MARKET SIZE, BY SURGICAL PROCEDU

Companies Mentioned

The leading players in the Congestive Heart Failure Market, which are profiled in this report, include:
  • Abbott Laboratories
  • Amgen Inc.
  • AstraZeneca
  • Bayer AG
  • Biotronik
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Company
  • CVRx, Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • HeartWare International Inc.
  • Johnson & Johnson
  • Medtronic plc
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • ResMed
  • Sanofi S.A.
  • Teleflex Incorporated
  • Thoratec Corporation

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages195
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 6.79 Billion
Forecasted Market Value ( USD ) by 2030 $ 10.54 Billion
Compound Annual Growth Rate7.3%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Congestive Heart Failure Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Congestive Heart Failure Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 91 Pages
  • Global
From
Heart Failure Software Market by Delivery Mode, Deployment - Global Forecast 2025-2030 - Product Image

Heart Failure Software Market by Delivery Mode, Deployment - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Heart Failure Therapeutics Market by Treatment, Type, Stage, End User - Global Forecast 2025-2030 - Product Image

Heart Failure Therapeutics Market by Treatment, Type, Stage, End User - Global Forecast 2025-2030

  • Report
  • 183 Pages
  • Global
From
Chronic Heart Failure - Epidemiology Forecast - 2034 - Product Image

Chronic Heart Failure - Epidemiology Forecast - 2034

  • Report
  • 165 Pages
  • Global
From
Acute Heart Failure (AHF) Therapeutics - Global Strategic Business Report - Product Image

Acute Heart Failure (AHF) Therapeutics - Global Strategic Business Report

  • Report
  • 299 Pages
  • Global
From

About the Congestive Heart Failure Market

Congestive Heart Failure (CHF) is a condition in which the heart is unable to pump enough blood to meet the body's needs. It is a common form of heart disease and is the leading cause of hospitalization in the United States. CHF is a progressive condition, meaning that it can worsen over time. Symptoms of CHF include shortness of breath, fatigue, and swelling in the legs and feet. Treatment for CHF typically includes lifestyle changes, medications, and in some cases, surgery. The CHF market within the context of cardiology is a rapidly growing one. It is estimated that over 5 million people in the United States are living with CHF, and this number is expected to increase in the coming years. As such, there is a need for new and innovative treatments to help manage the condition. Some companies in the CHF market include Novartis, Amgen, and Merck. These companies are developing new treatments and therapies to help manage the condition. Additionally, there are a number of smaller companies that are developing new technologies to help diagnose and monitor CHF. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.